188 related articles for article (PubMed ID: 16425574)
1. Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria.
Tse KC; Li FK; Tang S; Tang CS; Lai KN; Chan TM
Lupus; 2005; 14(12):947-52. PubMed ID: 16425574
[TBL] [Abstract][Full Text] [Related]
2. A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade.
Tse KC; Lam MF; Tang SC; Tang CS; Chan TM
Lupus; 2007; 16(1):46-51. PubMed ID: 17283585
[TBL] [Abstract][Full Text] [Related]
3. Antiproteinuric effect of angiotensin-converting enzyme inhibitors and an angiotensin II receptor blocker in patients with lupus nephritis.
Kitamura N; Matsukawa Y; Takei M; Sawada S
J Int Med Res; 2009; 37(3):892-8. PubMed ID: 19589275
[TBL] [Abstract][Full Text] [Related]
4. Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy.
Kanda H; Kubo K; Tateishi S; Sato K; Yonezumi A; Yamamoto K; Mimura T
Lupus; 2005; 14(4):288-92. PubMed ID: 15864915
[TBL] [Abstract][Full Text] [Related]
5. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
Esnault VL; Ekhlas A; Nguyen JM; Moranne O
Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors.
Seeman T; Pohl M; Misselwitz J; John U
Kidney Blood Press Res; 2009; 32(6):440-4. PubMed ID: 20016211
[TBL] [Abstract][Full Text] [Related]
7. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade.
Ferrari P; Marti HP; Pfister M; Frey FJ
J Hypertens; 2002 Jan; 20(1):125-30. PubMed ID: 11791035
[TBL] [Abstract][Full Text] [Related]
8. Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients.
Montanaro D; Gropuzzo M; Tulissi P; Vallone C; Boscutti G; Mioni R; Risaliti A; Baccarani U; Adani GL; Sainz M; Bresadola F; Mioni G
Transplant Proc; 2005 Mar; 37(2):991-3. PubMed ID: 15848600
[TBL] [Abstract][Full Text] [Related]
9. ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis.
Woo KT; Lau YK; Wong KS; Chiang GS
Kidney Int; 2000 Dec; 58(6):2485-91. PubMed ID: 11115082
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.
Esteghamati A; Noshad S; Jarrah S; Mousavizadeh M; Khoee SH; Nakhjavani M
Nephrol Dial Transplant; 2013 Nov; 28(11):2823-33. PubMed ID: 24009294
[TBL] [Abstract][Full Text] [Related]
11. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria.
Kincaid-Smith P; Fairley K; Packham D
Nephrol Dial Transplant; 2002 Apr; 17(4):597-601. PubMed ID: 11917051
[TBL] [Abstract][Full Text] [Related]
12. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
Matsuda H; Hayashi K; Saruta T
J Hum Hypertens; 2003 Apr; 17(4):271-6. PubMed ID: 12692572
[TBL] [Abstract][Full Text] [Related]
13. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
Pathak JV; Dass EE
Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
[TBL] [Abstract][Full Text] [Related]
14. ACEI and ARB combination therapy in patients with macroalbuminuric diabetic nephropathy and low socioeconomic level: a double-blind randomized clinical trial.
Titan SM; M Vieira J; Dominguez WV; Barros RT; Zatz R
Clin Nephrol; 2011 Oct; 76(4):273-83. PubMed ID: 21955862
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of renoprotective approaches for persistent proteinuria in lupus nephritis: more than just immunosuppression.
Castro M; Ugolini-Lopes M; Borba EF; Bonfá E; Seguro LPC
Lupus; 2018 Dec; 27(14):2215-2219. PubMed ID: 30394834
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J
Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
[TBL] [Abstract][Full Text] [Related]
17. Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade.
Agarwal R
Am J Physiol Renal Physiol; 2003 Apr; 284(4):F863-9. PubMed ID: 12505865
[TBL] [Abstract][Full Text] [Related]
18. Effects of ramipril and valsartan on proteinuria and renal function in patients with nondiabetic proteinuria.
Bilić M; Munjas-Samarin R; Ljubanović D; Horvatić I; Galesić K
Coll Antropol; 2011 Dec; 35(4):1061-6. PubMed ID: 22397239
[TBL] [Abstract][Full Text] [Related]
19. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial.
Saklayen MG; Gyebi LK; Tasosa J; Yap J
J Investig Med; 2008 Apr; 56(4):714-9. PubMed ID: 18382267
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment by ACE inhibitors and angiotensin receptor blockers in children with Alport syndrome.
Zhang Y; Wang F; Ding J; Zhang H; Liu X; Wang S; Xiao H; Yao Y; Liu J; Zhong X; Guan N; Su B; Wu G; Yu L
Pediatr Nephrol; 2016 Jan; 31(1):67-72. PubMed ID: 26248473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
